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Summary: Patients receiving multiple whole blood transfusions often experience adverse clinical Symptoms
caused by leukocytes. In the present study, the efficacy and safety of a polyester filter for leukocytes (Sepacell
R-500) was evaluated. Donor units of whole blood and red cell concentrate stored for varying lengths of time
were filtered. Emphasis was placed on humoral parameters indicative of release and/or activation reactions
of granulocytes (neutral proteinase elastase, lysozyme, aggregation, chemiluminescence) and erythrocytes
l (lactate dehydrogenase, plasma haemoglobin). Nonspecific adsorption effects were investigated by plasma
,. protein determinations (albumin, a2-macroglobulin). A complete blood cell count äs well äs values of
1 haemoglobin and haematocrit were determined. Sepacell R-500 proved to be a highly efficient filter to the
j leukocyte depletion of blood. Our results of erythrocyte and granulocyte related humoral parameters provided
no significant evidence of filtration mediated activation or releasing reactions of clinical consequence.
Introduction chemical or mechanical Stimulation. Reactive oxygen
^ t _ . - - , , , species and neutral proteinase have been implicatedRepeated transfusions of blood are commonly asso- ^ ̂  thogenesi3 of acute tissue injuryj particularly
ciated with the occurence of nön-haemolytic febnle ^ ̂  Jhe activation of granuiocyte oxidative
reactions. These canbepreventedorlessenedbytrans- metaboüsm and neutral proteinase release have been
fusing blood which h*s been freed from leukocytes. detectedduringextracorporealcircuitproceduressuch
Various procedures are currentiy used to produce as haemodialysis and cardiopulmonary bypass
relatively leukocy te~ppor blood. Filtration techmques n_\y\
are the most common (l — 5). In the past, investiga- _ ,
tions concerning the filtration of blood using variöus ""* Present investigation thus explores levels of re -
filter types have concenträted on the degree of deple- evant humoral and <*llular Parameters followmg fil-
tion of distinct cell types (1). Information concerning tration usif a 1^ filte5 (Seupacdl R-50°) whose
the mediated activation and release reactions of the leukocyte-depletion efficacy has been previously doc-
differing cell types following mechanical filtration ume»ted (13> 14)·
procedures is not available. The cell most likely to be In this investigation, we have concenträted on the
implicated in adverse reactions is the neutrophil gran^ behaviour of those parameters indicative of the release
ulocyte due to its signifieant pathogenic capabiüty. and/or activation of specific cell types. All experi-
These cells can discharge large amounts of toxic oxy- ments were performed with whole blood and red cell
gen species and lysosomal neutral proteinases upon cpncentrates stored over varying lengths of time.
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Materials and Methods
Whole blood and red cell concentrate
Whole blood in citrate-phosphate-dextrose (Fenwal Laborato-
ries, Deerfield, IL, USA) and red cell concentrates derived from
whole blood were used. At the time of investigation samples
were l, 5 or 10 days old. Samples were stored at 4 °C.
Filter
All experiments were performed using Sepacell R-500 leukocyte
removal füters (Asahi Medical Co. Ltd., Tokyo, Japan; distrib-
uted by Diamed, Cologne, FRG). The Sepacell filter consists
of polycarbonate densely packed with sheets of polyester fibers.
The filters were used according to the manufacturer's instruc-
tions. Aliquots of whole blood were obtained pre- and post-
filtration.
Haematology
Red cell, leukocyte, and platelet counts, haemoglobin and hae-
matocrit were determined using a Coulter counter S-Plus IV
(Coulter Electronics, Hialeah, Fla, USA).
Plasma chemistry
Plasma (12000 g, 10 min) was frozen and stored at — 70°C.
Standard procedures were apph'ed for the determination of
lactate dehydrogenase, plasma haemoglobin, granulocyte elas-
tase äs elastase-ocrproteinase inhibitor complex (complexed
elastase) and lysozyme (15 — 17). Albumin and oc2-macroglob-
ulin were determined by nephelometric methods.
Isolation of granulocytes
Granulocytes from normal blood donors were isolated from
the interface of a two-step discontinuous Percoll gradient (18).
Granulocyte functional tests r
Granulocyte aggregation was measured using donor granulo-
cytes (l l O7 cells). Fifty microliters of unit plasma were
brought to a final volume of l ml. Aggregation responses were
quantitated from the increases in light transmittance (19).
Luminol-enhanced chemiluminescence of donor granulocytes
(0.5 105 cells) was induced with zymosan, a particulate Stim-
ulus, and amplified with the addition of autologous unit plasma
(CL 1). Controls (Kl) without zymosan were also run (20).
Chemiluminescence was measured with the Biolumat LB 9505
(Berthold, FRG) at 37 °C.
Two chemiluminescence parameters were calculated from the
measurements:
(i) peak maximum counts/min (per 0.5 l O5 granulocytes) for
the Stimulation reaction (CL1) äs well äs for the control
(Kl), representing the oxygenation capacity and the native
chemiluminescence, respectively.
(ii) peak time values (min) seen äs time in minutes required to
reach the peak maximum, representing the degree of recep-
tor affinity and/or concentration.
Statistics
Statistical analyses were performed by Studenfs paired Mest.
Significant differences between pre- and post-filtration values
are given by: 2 p < 0.05*, 2 p < 0.01** and 2 p < 0.001***..
Results
The results of filtration experiments using whole
blood and red cell concentrate units stored from l to
10 days are given in table l and table 2, respectively.
Leukocytes and thrombocytes were removed to a
significant degree from whole blood äs well äs from
red cell concentrates. The number/ of erythrocytes, on
the other hand, remained unchanged by the filtration
process.
Certain humoral parameters are indicative of eryth-
rocyte integrity during storage and before and after
filtration. Plasma haemoglobin and lactate dehydn>
genäse levels increased with the duration of storage.
Filtration-dependent increases were observed in
plasma haemoglobin levels in red cell concentrate
units from the first day of storage and in whole blood
after 10 days of storage.
Levels of granulocyte secretory products in plasma
(complexed elastase, lysozyme) increased with the du-
ration of storage time and remained unäffected by
filtration.
Levels of plasma proteins such äs albumin and the
protease inhibitor a2-macroglobulin were unäffected
by either the duration of storage ör filtration, äs was
also the case for haemoglobin and haematocrit. För
22 units of whole blood and 15 units pf red cell
concentrate the mean (± SD) post-filtration weight
was 90.2% (± 4.9%) and 85.6% (± 5,6%) of the pre-
filtration weight, respectively, and the mean (± SD)
filtration time was 5.4 min (± 1.5 min) and 5.1 min
(± 2.6 min), respectively. However, 10 of the 37 units
required more than 20 min for filtration. These units
were < 5 days old (2 units of whole blood, 8 units of
red cell concentrate).
Neither aggregation- nor plasma-induced chemilur
minescence (Kl) increased after filtration. Chemilu-
minescence induced by zymosan plus plasma (CL1)
decreased after filtration.
Discussion
In the present investigation whole blood and red cell
concentrates, stored for different times, were effi-
ciently freed of leukocytes and platelets using a po-
lyester leukocyte removal filter (Sepacell R-500). The
absolute number of leukocytes rernäining in a unit of
filtered blood (ca. 0.1 109/1) was far less than that
(0.5 109/unit) usually required to produce non-
haemolytic febrile transfusion feactions in a sensitized
patient (21). These results for leukocyte depletion are
comparable with those previously reported for this
type of filter (12, 13).
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The fact that platelets are removed to a large degree,
however, makes this filter unsuitable for the prepa-
ration of leukocyte-poor platelet concentrates (22).
Similar values for haemoglobin, haematocrit and
erythrocytes, before and after filtration, together with
a lower post-filtration weight indicate that erythro-
cytes and plasma were proportionally removed by
filtration. The loss, however, was small.
Apart from the question of the efficacy of this filter
medium, the emphasis of this investigation has been
placed on parameters indicative of the activation and
integrity of granulocytes and erythrocytes and sub~
sequent product release. Frequently observed adverse
clinical reactions to other models of extracorporeal
blood circuits, such äs haemodialysis and cardiopul-
monary bypass, have been ascribed to granulocyte
activation with the concomitant generation of large
amounts of toxic oxygen species (e. g. Superoxide an-
ion, hydrogen peroxide), discharge of primary and
secondary granule contents (e. g. elastase, cathepsin)
and complement activation (7—12).
In the case of steadily increasing pre-filtration values,
changes in the concentrations of the relative plasma
Parameters can be attributed to the duration of blood
storage; whereas in the case of increased post-filtra-
tion values such changes can be attributed to the
mechanical procedure of filtration itself.
Changes of the first type were observed for lactate
dehydrogenase, plasma haemoglobin, complexed elas-
tase and lysozyme. The increased concentrations are
directly related to the duration of storage. These
changes are within the ränge of previously reported
changes observed äs a result of long storage times
(23, 24).
A filtration-related increase was observed for plasma
haemoglobin. This increase was more drastic and the
onset occured earlier in red cell concentrates. This is
indicative of the increased fragility of erythrocytes
due to prolpnged storage. Plasma lactate dehydrogen-
ase does not share this behaviour; it is probably
inactivated (25). Due to the small plasma volume in
red cell concentrates, relatively high plasma haemo-
globin values should not be injurious to the recipient.
Changes in the levels of granulocyte secretory prod-
ucts, such äs elastase complexed with its natufal in-
hibitor (complexed elastase) and lysozyme, did not
occur. In contrast, increases in compexed elastase
values öf more than 10-times above normal have been
observed during haemodialysis, depending on the type
of dialysis membrane used (8 — 11). These results
based on humoral parameters do not indicate a fil-
tration-mediated impairment of the integrity of gran-
ulocytes, whereas erythrocytes were slightly fragile
after 5 days of storage. It has been shown that plasma,
after travelling through various extracorporeal cir-
cuits, äs commonly occurs in techniques such äs fil-
tration cytapheresis (26), haemodialysis (7) and car-
diopulmonary bypass (12), generates distinct granu-
locyte-activating products. These complement-split-
ting products (C5a) and immune complexes are potent
Stimuli, causing increases in aggregation and respi-
ratory burst activity (chemiluminescence) of granu-
locyte target cells.
Granulocyte activation products in plasma, however,
have not been observed using this type of filter. In-
creasing values for chemiluminescence and aggrega-
tion did not occur upon Stimulation of donor gran-
ulocytes with plasma alone (Kl) or in combination
with a particulate Stimulus such äs zymosan (CL1).
Decreased post-filtration chemiluminescence values
following Stimulation with zymosan plus autologous
plasma (statistically significant for red cell concen-
trate), are the result of quenching by increased plasma
haemoglobin values of added plasma (20).
Plasma protein adsorption by the polyester fibre Soft-
ware was not observed, äs indicated by unchanged
plasma protein values for albumin and oc2-macroglob-
ulin.
In about one fourth of the total number of filters
evaluated, the filtration rate was slow, requiring more
than 20 min. As these units were > 5 days old they
presumably contained enough microaggregates to
block the pores of the filter. This fact and the above
mentioned observation äs to the higher fragility of
erythrocytes > 5 days old support the Suggestion of
using blood less than 3 days old (27). Considering the
present results, it is apparent that Sepacell R-500 is a
highly efficient filter for leukocyte depletion of blood.
No evidence of erythrocyte- and granulocyte-releasing
and/or activation products were detected in post-
filtration plasma for storage times of less than 5 days.
Adverse clinical Symptoms due to filtration using this
filter are, therefore, highly improbable.
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